SNV1521

Phase 1Small molecule

SSynnovation Therapeutics, Inc.

SNV1521 is one of 82 small molecule programs targeting Advanced Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorRecruiting

Pancreatic CancerNot yet recruiting

Advanced Solid TumorPhase 1

Recruiting

Pancreatic CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Cyclophosphamid

EEssen Biotech

Preclinical

1 10

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Advanced Solid Tumor

NCT06220864

Q2 2029

Phase 1Not yet recruiting

Pancreatic Cancer

NCT07756281

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Not yet recruiting·SSynnovation Therapeutics, Inc.·Phase 1·NCT07756281·40 enrolled

Advanced Solid Tumor1 trial

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

Recruiting·SSynnovation Therapeutics, Inc.·Phase 1·NCT06220864·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SNV1521. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNV1521 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNV1521. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Synnovation Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSynnovation Therapeutics, Inc.

SNV1521

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Pancreatic Cancer1 trial

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News